An advisory panel to Japan’s ministry of health, labour and welfare has recommended for approval Novartis AG/AveXis Inc.’s gene therapy Zolgensma (onasemnogene abeparvovec), for the treatment of spinal muscular atrophy (SMA) type 1.
Eyes On Pricing As Zolgensma Moves Closer To Japan Market
Possible May Launch?
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.
